Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 53

Posts Tagged ‘diabetes’

Cities Changing Diabetes

Posted by fidest press agency su martedì, 21 gennaio 2020

Milano 23 gennaio ore 09.30 – 13.30 Sala “Marco Biagi” Palazzo Lombardia – Nucleo 4 Via Melchiorre Gioia 37 L’insorgenza del diabete legato agli stili di vita dei cittadini è un problema emergente di sanità pubblica. Per questo motivo, la Città Metropolitana di Milano è entrata a far parte, insieme a Roma ad altre 24 città nel mondo, del progetto internazionale Cities Changing Diabetes, l’iniziativa realizzata in partnership tra University College London (UCL) e il danese Steno Diabetes Center, sviluppata in Italia dall’Health City Institute, in partnership con ANCI, l’Istituto Superiore di Sanità e con il contributo non condizionato di Novo Nordisk, che ha l’obiettivo di valutare l’impatto dell’urbanizzazione sulle malattie croniche non trasmissibili e promuovere progetti per salvaguardare la salute e prevenire la malattia.Con questo ATLAS viene realizzata una prima mappatura dello stato di salute attuale dei cittadini di Milano per fornire una base di studio e costruire un programma di azioni che possa accompagnare lo sviluppo del territorio con interventi volti a promuovere la salute e il benessere dei cittadini.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Kuwait Hospital Market Review & Forecast Report 2012-2022 – Rising Cases of Diabetes in GCC & Kuwait

Posted by fidest press agency su mercoledì, 6 novembre 2019

The “Kuwait Hospital Market Outlook to 2022- By Public and Private Hospitals, By Inpatients and Outpatients, By General and Specialty Hospital and By Region (Al Asima, Hawalli, Al Farwaniya, Al Ahmadi, Al Jahra and Mubarak Al-Kabeer)” report has been added to’s offering.In terms of revenue, the Kuwait hospital market has registered a constant growth with positive CAGR in the last five years (2012-2017). The majority of the healthcare sector in Kuwait is controlled by the Ministry of Health. Private participation in the healthcare sector is considerably low. The healthcare services in public sector hospitals are at highly subsidized rates. Owing to this, the number of outpatients and inpatients in public sector hospitals is significantly higher than in the private sector. However, the majority of the revenues generated in the hospital market is from the private sector hospitals. This is due to the enormous difference in prices for healthcare services in public and private sector hospitals.The Kuwait Hospital Market is expected to grow at a positive CAGR from 2018-2022. Kuwait is a high income class country and the demand for high end luxurious stay at hospitals is increasing among Kuwaiti residents. The Kuwait hospital market is likely to witness the addition of numerous hospitals in the next five years, with a mix of publicly and privately owned hospitals. Specialty care hospitals for Maternity and Pediatrics, Infectious Disease and allied medicines including school health services & dentistry are likely to open in the future. The number of available hospital beds is also likely to grow significantly with the growth in the number of hospitals.The revenue generated from private sector hospitals will continue to dominate the hospital market in Kuwait as private participation is likely to increase and so is the cost of private healthcare. It is expected that in the next five years, a number of general hospitals will come up in Kuwait. However, owing to the rising incidences and need for specialized tertiary and quaternary care, the number of specialized hospitals will be more in comparison to general hospitals. It is anticipated that by 2022, the revenue generated from outpatients will be greater than the revenue from inpatients due to the anticipated rise in the number of outpatients seeking private healthcare.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

55th Annual Meeting of the European Association for the Study of Diabetes

Posted by fidest press agency su giovedì, 12 settembre 2019

POXEL S.A. (Euronext – POXEL) A biopharmaceutical company dedicated to the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be attending and presenting a session at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), held at the Fira Barcelona Gran Via conference center in Barcelona, Spain from September 16 – 20, 2019. The session will be chaired by leading academic diabetes expert, Ralph DeFronzo, M.D., Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio and Deputy Director of the Texas Diabetes Institute, part of University Health System, San Antonio, Texas. The purpose of the session will be to discuss the therapeutic potential of Poxel’s lead drug candidate, Imeglimin, a novel treatment approach for type 2 diabetes in various patient populations, and to present the detailed Phase 3 TIMES 1 results in Japanese patients. The session will be followed by an open Q&A.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

20th Annual Children with Diabetes Friends for Life Conference

Posted by fidest press agency su sabato, 20 luglio 2019

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will launch a new microsite, with a focus on educating, empowering, and mobilizing the diabetes community to drive affordable access to medical devices and medications. The site will be launched in connection with the Company’s participation at the 20th Annual Children with Diabetes Friends for Life conference taking place in Orlando, Florida, July 17-19, 2019.This unique educational resource is intended to empower people with diabetes to become self-advocates by providing them with tips, helpful tools, customizable templates, and testimonials from others who have become successful self-advocates. The interactive site will launch in the U.S. and is designed to also help continue acceleration of coverage for the Company’s new Omnipod DASH™ Insulin Management System (Omnipod DASH System).
Insulet will have a robust presence at the meeting and will feature its new, innovative Omnipod DASH System in a product theater, a variety of hands-on, interactive product demonstrations, and other events during the conference and at its exhibit booth (#101). Insulet will also be offering saline trials to newly diagnosed families interested in trialing the Omnipod System, and will also hold multiple focus groups.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Therapeutic Procedure Could End Daily Insulin Injections for Type 2 Diabetes Patients

Posted by fidest press agency su lunedì, 10 giugno 2019

Fractyl Laboratories Inc. (Fractyl), today announced the presentation of interim data from the investigator-initiated INSPIRE clinical trial in collaboration with Fractyl showing Revita™ DMR, a same-day therapeutic procedure, can help eliminate the need for daily insulin injections for type 2 diabetes (T2D) patients. This data will be presented at the American Diabetes Association’s 79th Scientific Sessions in San Francisco on Sunday, June 9 from 12 pm to 1 pm. The presentation (1156-P) is entitled, “Duodenal Mucosal Resurfacing (DMR) Combined with GLP-1-RA May Eliminate Insulin Therapy and Improve Metabolic Health in Type 2 Diabetes.”
Building on years of research about the gut’s critical role as a root cause of metabolic disease, the Revita duodenal mucosal resurfacing (DMR) procedure aims to reset key metabolic pathways, including insulin resistance, to prevent and even reverse metabolic disease progression. This same-day, outpatient endoscopic procedure uses heat to resurface the lining of the upper intestine (duodenum) in a minimally invasive, outpatient procedure. The therapy is designed to target the root cause of metabolic syndrome in the duodenum, leading to significant improvements in metabolic disease parameters, reduced need for medication usage, and greater patient satisfaction with their therapy.
The INSPIRE study completed enrollment at 16 patients, out of which 13 patients have reached the six-month follow-up, and 11 of 13 (85%) are insulin-free. The remaining three patients are still in the trial but have not reached their six-month follow-up for this interim analysis. In addition, patients have seen nearly 45 percent reduction in liver fat on MRI-PDFF (from a baseline of 8.5 percent absolute liver fat), along with significant improvements in blood pressure and weight.Previous clinical studies of Revita DMR in more than 200 patients have demonstrated sustained improvements in blood glucose levels, insulin resistance measures, liver fat, cardiovascular risk markers, and weight loss, unaided by any lifestyle intervention, through one year of follow-up. In all clinical studies, Revita DMR was well-tolerated and demonstrated an acceptable safety profile.“Type 2 diabetes is complicated with many severe co-morbidities, often managed with multiple daily medications. But with Revita DMR, we continue to see positive clinical effects on diabetes, fatty liver, and cardiovascular disease, after treatment,” said Juan Carlos Lopez-Talavera, M.D., Ph.D., chief medical officer of Fractyl. “By targeting the root cause of metabolic disease, Revita DMR can provide significant and sustained disease modification for the patient, in addition to reducing their disease management burden.” Non-alcoholic fatty liver disease (NAFLD/NASH) and T2D have both reached epidemic levels in the United States and around the world, and there are currently no FDA-approved treatments for NAFLD/NASH. Of particular concern, are the estimated 18 million Americans who have both conditions, and hence much higher risk of negative outcomes.1Data presented at ILC 2019 showed that Revita DMR can generate significant improvements in people with both NAFLD/NASH and T2D conditions.The first U.S. clinical trial for Revita DMR is currently taking place at five sites and is recruiting T2D patients on oral anti-diabetic medications with inadequately controlled diabetes. For a full list of inclusion and exclusion criteria, visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Senseonics Announces Extension of Distribution Agreement with Roche Diabetes Care

Posted by fidest press agency su mercoledì, 6 febbraio 2019

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced an extension of its distribution agreement with Roche Diabetes Care. As extended, the agreement now runs through January 31, 2021. Under terms of the extended agreement, Roche will continue its role as Senseonics exclusive distributor in Europe, the Middle East and Africa, excluding Scandinavia and Israel. In addition, the agreement has been expanded to provide Roche with exclusive distribution rights in 17 additional countries, including Brazil, Russia, India and China, as well as select markets in the Asia Pacific and Latin American regions.Senseonics also announced preliminary revenue results for fourth quarter and full year 2018. Unaudited preliminary revenue is expected to be $8.0 million for the fourth quarter of 2018 and $19.7 million for the full year 2018, compared to $2.9 million for the fourth quarter of 2017 and $6.4 million for the full year 2017. As of December 31, 2018, cash and cash equivalents were $136.8 million and outstanding indebtedness was $67.7 million.
“We are excited about the ongoing and incremental commitment from Roche, both from a geographic expansion and volume perspective. We believe that the positive reception that the Eversense® CGM System has received in Europe is validation that patients and clinicians are experiencing the transformative power of a long-term CGM system. We look forward to our expanded relationship with Roche in which we have made market expansion, with access and volume in existing and new countries, a strategic priority,” said Tim Goodnow, President and Chief Executive Officer.Mr. Goodnow continued, “We are also pleased with our fourth quarter and full year revenue results. In 2018 we achieved several significant accomplishments including the launch of Eversense in the U.S. and the extended life Eversense® XL system in Europe. The U.S. launch is progressing along with our expectations – feedback from patients has been encouraging, and we are more inspired now than ever about the potential life-enhancing benefits this product offers people with diabetes.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

November is National Diabetes Awareness Month

Posted by fidest press agency su giovedì, 1 novembre 2018

A time when communities across the country team up to bring attention to diabetes to raise awareness about the everyday realities of diabetes and to offer support to those who have been diagnosed.
World Diabetes Day (WDD) is November 14th. It was created in 1991 by IDF and the World Health Organization in response to growing concerns about the escalating health threat posed by diabetes. In more than 160 countries around the world, people will participate in events and activities which raise awareness about diabetes. The activities include rides, walks, open houses, and lighting historic buildings and landmarks in blue, the official color for diabetes awareness.There are two main types of diabetes. Type 1 diabetes is an autoimmune disease that often is diagnosed in youth and requires insulin shots for the rest of life while Type 2 shows up primarily in adults and is associated with diet, obesity, and a sedentary lifestyle.
Throughout the month, the Juvenile Diabetes Cure Alliance (JDCA) is promoting awareness for Type 1 Diabetes, which impacts 20-30 million people globally. Over the past ten years, the number of people with T1D has grown by 30%, and by 2030, is expected to impact more than 50 million people.The lifetime cost of care for a single person living with T1D amounts to $11 million. This equates to $14 billion in health care expenditures in the U.S. per year, and $280 billion globally, 5 percent of all global health expenditures. Furthermore, the cost of care for T1D is rising dramatically, the price of a 10-millimeter vial of insulin shot up from $40 in 2001, to more than $275 today, a 588 percent increase.The JDCA, continuing efforts to push major diabetes organizations to increase cure research funding for type 1 diabetes, launched its 4th Annual More for a T1D Cure Petition on September 4, 2018. For the 2017 fiscal year, the Juvenile Diabetes Research Foundation spent only 38 percent of its income on cure research and the American Diabetes Association spent only 4 percent. Both figures are underwhelming and are cause for concern among the type 1 diabetes community. The petition, which has a goal of 200,000 signatures, has garnered 190,000 signatures to date.“There will be no cure for type 1 diabetes in our lifetime unless we see a drastic shift in the amount of money going toward cure research,” says Phil Shaw General Manager of the JDCA. “Supporting cure research is the number one priority of the type 1 diabetes community.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Insulet Partners with the International Diabetes Federation Europe to Support Advocacy Activities Across the Continent

Posted by fidest press agency su mercoledì, 11 luglio 2018

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it has entered into a partnership with the European Region of the International Diabetes Federation (IDF Europe) to collaborate on regional advocacy activities. This partnership provides broader access for Insulet to more closely engage with the European diabetes community.“We are delighted to partner with IDF Europe, which represents 71 national diabetes organizations in 46 countries across Europe,” said DJ Cass, General Manager, Insulet Europe. “Through its advocacy work, IDF Europe’s mission is to improve the health outcomes of its 570,000 members and we look forward to working more closely with them through this powerful collaboration starting with the Youth Leadership Camp in the Czech Republic.” The Youth Leadership Camp is an annual event organized by IDF Europe to provide a unique experience for young people with diabetes to learn skills to become ambassadors for change, while sharing knowledge and interacting with their peers from multiple countries. The 8th edition of the IDF Europe Youth Leadership Camp is taking place in the Czech Republic, July 8-14, 2018.“There are one million people living with Type 1 Diabetes in Europe and IDF welcomes the support of key industry partners, such as Insulet, so we can work together to advocate for improved diabetes care,” said Prof. Dr. Sehnaz Karadeniz, Chair, IDF Europe Region. “The corporate panel at our Youth Leadership Camp is always well received by participants and we look forward to another interactive session this year. IDF Europe values the essential role youths play in raising diabetes awareness as they represent the voices of the future and we encourage them to play an active role advocating for change.” Insulet’s partnership with IDF Europe will also include joint activities for World Diabetes Day on November 14, 2018 and several additional advocacy activities throughout the year to increase recognition for the diabetes community and to support policy change.

Posted in Estero/world news, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Stand up: It could help you lose weight

Posted by fidest press agency su giovedì, 1 febbraio 2018

Sophia Antipolis. You might want to read this on your feet. A new study published today in the European Journal of Preventive Cardiology1 found that standing instead of sitting for six hours a day could prevent weight gain and help people to actually lose weight.Prolonged sitting has been linked to the obeSophia Antipolissity epidemic, cardiovascular disease, and diabetes. Europeans sit for up to seven hours a day, and even physically active people may spend most of the day in a chair. This paper examined whether standing burns more calories than sitting. The researchers analysed results from a total of 46 studies with 1,184 participants in all. Participants, on average, were 33 years old, 60% were men, and the average body mass index and weight were 24 kg/m2 and 65 kg, respectively.The researchers found that standing burned 0.15 kcal per minute more than sitting. By substituting standing for sitting for six hours a day, a 65 kg person would expend an extra 54 kcal a day. Assuming no increase in food intake, that would equate to 2.5 kg in one year and 10 kg in four years.
Senior author Professor Francisco Lopez-Jimenez, Chief of Preventive Cardiology at the Mayo Clinic in Rochester, US, said: “Standing not only burns more calories, the additional muscle activity is linked to lower rates of heart attacks, strokes, and diabetes, so the benefits of standing could go beyond weight control.” The gap in energy expenditure between standing and sitting could be even greater than the study found. Participants were standing still, while in reality people make small movements while standing. “Our results might be an underestimate because when people stand they tend to make spontaneous movements like shifting weight or swaying from one foot to another, taking small steps forward and back. People may even be more likely to walk to the filing cabinet or trash bin,” said Professor Lopez-Jimenez.he authors concluded that replacing standing for sitting could be yet another behaviour change to help reduce the risk of long term weight gain. They suggest more research is needed to see whether such a strategy is effective and practical. Data is also needed, they say, on the long term health implications of standing for extended periods.Professor Lopez-Jimenez said: “It’s important to avoid sitting for hours at a time. Standing is a very good first step – no pun intended – to avoid this mindset of sitting interminably without moving. Who knows, it may also prompt some people to do a little more and take up some mild physical activity, which would be even more beneficial.”

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Presentazione del Diabetes Monitor e del Diabetes Web Report

Posted by fidest press agency su venerdì, 24 novembre 2017

istituto superiore sanitàRoma, 6 dicembre 2017, ore 10.00 Istituto superiore di sanità, Sala Bovet Viale Regina Elena, 299 Oltre tre milioni di persone ne soffrono in Italia – un numero destinato ad aumentare-, importanti ripercussioni a livello sanitario, sociale ed economico, e la costante necessità di un’attenta organizzazione dell’offerta sanitaria per gestirne correttamente il trattamento: il diabete è un’emergenza che occorre affrontare con un approccio a 360 gradi. Il primo passo è la raccolta e condivisione di informazioni sull’entità del fardello della malattia, e in un mondo sempre più digitale l’impatto del web e dei social media rappresenta una sfida e un’opportunità da sfruttare.Il Diabetes Monitor, giunto alla settima edizione, e il più recente Diabetes Web Report mirano ad analizzare le modalità di gestione della malattia, il suo trattamento, e il comportamento in rete in quest’ambito delle persone con diabete.

Posted in Medicina/Medicine/Health/Science, Roma/about Rome | Contrassegnato da tag: , , | Leave a Comment »

Barometer Report: 8% dei sedentari sviluppa il diabete

Posted by fidest press agency su mercoledì, 21 novembre 2012

Una dieta bilanciata, l’esercizio fisico e il controllo del peso riducono del 50% il rischio di sviluppare il diabete. Non è un caso che sono colpite dalla patologia l’8% delle persone che non praticano alcuna attività sportiva, contro l’1% dei soggetti che svolgono attività fisica in modo continuativo, e che i grandi obesi presentano un rischio di sviluppare il diabete superiore di 60 volte rispetto ai normopeso. È questa la fotografia scattata dall’Italian Barometer Report 2012, documento prodotto dall’Italian Barometer Diabetes Observatory (Ibdo) dell’Università di Tor Vergata e presentato al Senato in un convegno. Il messaggio che emerge è che spesso «le scelte relative agli stili di vita possono essere influenzate da fattori ambientali, come le strutture sociali, le condizioni culturali e politiche e l’ambiente in cui si vive». Tanto che la diffusione della malattia risulta di 5 volte inferiore tra i laureati o con diploma superiore , in confronto a chi ha solo la licenza elementare e ancora una volta si conferma che sono i cittadini del Sud a essere i più colpiti: «il 7,8% dei lucani e il 7,6% dei calabresi sono diabetici, contro il 2,6% degli abitanti di Bolzano, il 3,4% dei valdostani e dei veneti, il 3,6% dei lombardi». In generale, anche i livelli di attività fisica e di obesità sono soggetti a differenze regionali: «la percentuale di persone completamente sendentarie per esempio è vicina al 15% in Trentino, mentre supera il 60% in Sicilia ed è attorno al 50% in Calabria, Campania e Puglia». E in questo quadro l’arma migliore per combattere la patologia, che «uccide ogni anno 27.000 italiani tra i 20 e i 79 anni», rimane la prevenzione: «Grazie a stili di vita adeguati» commenta Antonio Tomassini, presidente della XII commissione Igiene e sanità del Senato «si possono ottenere grandi risultati anche dal punto di vista economico». Ma anche la prevenzione secondaria riveste una importanza fondamentale: «Il buon controllo della patologia da attuare subito dopo la diagnosi e un trattamento precoce e intensivo dei principali fattori di rischio» aggiunge Agostino Consoli, coordinatore del Report 2012 e ordinario di Endocrinologia presso l’Uni versità di Chieti «come glicemia, ipertensione e colesterolo alto, riduce del 50% il rischio di gravi complicanze e di morte a distanza di 13 anni». D’altra parte, aggiunge Renato Lauro, presidente dell’Osservatorio e rettore dell’ateneo romano, «la lotta al diabete assorbe il 9% della spesa sanitaria italiana annuale, pesando sulle casse statali per 9,22 miliardi di euro, pari a 2.660 euro per ogni paziente».(fonte doctor news)

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

4° Changing Diabetes Barometer Forum

Posted by fidest press agency su sabato, 9 aprile 2011

Roma 12 aprile, ore 9-14 Tempio di Adriano Piazza di Pietra. Le patologie croniche non trasmissibili rappresentano una delle sfide più difficili per tutti i sistemi sanitari, sia nei Paesi industrializzati sia in quelli in via di sviluppo, a causa delle loro continua e inesorabile crescita. L’esempio più paradigmatico è rappresentato senz’altro dal diabete mellito: si stima che il numero di persone affette nel mondo crescerà dai 171 milioni del 2000 ai 366 milioni nel 2030. Anche nel nostro Paese, negli ultimi anni, si è assistito a una vera e propria esplosione del fenomeno: alla fine del secolo scorso il diabete interessava meno di 4 italiani su 100, oggi siamo a 5 su 100. Rispetto a 10 anni fa ci sono oggi in Italia quasi un milione di persone in più con diabete diagnosticato. Il 21 dicembre 2006, l’Assemblea Generale delle Nazioni Unite ha votato una Risoluzione che riconosce il diabete un problema di sanità pubblica per l’Umanità. La massima organizzazione internazionale ha riconosciuto, per la prima volta, una malattia non comunicabile come seria minaccia alla salute del pianeta, al pari di HIV/AIDS, tubercolosi e malaria. La Risoluzione impegna tutti gli Stati Membri a promuovere  politiche per la prevenzione e la cura del diabete, con particolare riferimento all’educazione, all’informazione e alla ricerca. Da diversi anni, in Italia le Associazioni di volontariato delle persone con diabete, le Società scientifiche e professionali e le Istituzioni hanno intrapreso un percorso comune di confronto e collaborazione, con l’obiettivo di unire impegno e risorse per affrontare le sfide che il diabete pone già oggi alla società. Una delle principali iniziative in tal senso è il Changing Diabetes Barometer Forum, capitolo italiano di un progetto internazionale che vede protagoniste le organizzazioni pubbliche e private coinvolte sulla malattia, ideato, promosso e sostenuto dal supporto non condizionato dell’industria farmaceutica Novo Nordisk. La quarta edizione del Forum italiano si svolgerà a Roma il 12 aprile, sotto l’Alto Patronato del Presidente della Repubblica, con il Patrocinio di Senato della Repubblica, Camera dei Deputati, Presidenza del Consiglio dei Ministri e dei numerosi Ministeri interessati e con il coinvolgimento di esperti e organizzazioni scientifiche nazionali e internazionali, politici e rappresentanti delle Istituzioni. Al centro del dibattito l’identificazione di misure atte a contenere quella che tutti ormai definiscono una delle grandi minacce del terzo millennio.

Posted in Cronaca/News, Medicina/Medicine/Health/Science, Roma/about Rome | Contrassegnato da tag: , , , | Leave a Comment »

Congresso American Diabetes Association

Posted by fidest press agency su martedì, 29 giugno 2010

Ingelheim, Germania, I risultati degli  Studi di fase III su Linagliptin, presentati per la prima volta in occasione della 70esima edizione del Congresso dell’American Diabetes Association (ADA), dimostrano che questo nuovo inibitore via sperimentale della dipeptidil peptidasi 4 (DPP-4) in sviluppo clinico, riduce la glicemia in maniera statisticamente significativa, clinicamente rilevante con il mantenimento di tali effetti nel tempo. Il controllo glicemico è stato valutato in termini di emoglobina glicata (HbA1c), di glicemia plasmatica a digiuno e di glicemia post-prandiale. Linagliptin è un farmaco sperimentale di Boehringer Ingelheim per la terapia del diabete mellito di tipo 2 in somministrazione giornaliera. In studi a scopo registrativo di fase III, Linagliptin ha dimostrato un profilo di sicurezza molto positivo, con una percentuale complessiva di eventi avversi paragonabile a placebo. Inoltre, linagliptin ha dimostrato di essere molto ben tollerato, di non avere ripercussioni sul peso corporeo, di non aumentare il rischio di interazioni con altri farmaci e, aspetto assai rilevante, di non aumentare il rischio di ipoglicemia, sia quando assunto da solo che in associazione a metformina o pioglitazone. Va notato che i livelli di glicemia plasmatica rilevati in pazienti diabetici con compromissione renale da lieve a moderata, sono stati paragonabili a quelli riscontrati in pazienti diabetici con normale funzionalità renale.1 Ciò suggerisce che linagliptin, che viene escreto per via prevalentemente non renale, può avere caratteristiche farmacologiche specifiche mai riscontrate prima in altri farmaci di questa stessa classe farmacologica innovativa.8 I dati suggeriscono che Linagliptin non richiederebbe aggiustamenti di dosaggio nei pazienti con diabete di tipo 2, indipendentemente dallo stadio di compromissione renale.  I risultati di quattro studi multi-centrici randomizzati in doppio cieco con gruppo di controllo, della durata di 24 settimane, dimostrano che Linagliptin, sia in monoterapia verso  placebo che in associazione ad altri antidiabetici orali d’uso comune, riduce significativamente la glicemia. Inoltre, tali riduzioni sono state accompagnate da miglioramenti significativi della funzionalità delle cellule beta pancreatiche. E’ noto che il deterioramento della funzionalità delle cellule beta è un fattore chiave nella progressione del diabete di tipo 2. I risultati di un ulteriore studio dimostrano, inoltre, che linagliptin in monoterapia è superiore in termini di riduzione della glicemia, sia rispetto a placebo, che a voglibose l’inibitore dell’alfa-glucosidasi più diffuso in Giappone. “Molti pazienti con diabete di tipo 2 in terapia con antidiabetici tradizionali non riescono a raggiungere il controllo glicemico e a mantenerlo nel tempo. A ciò si aggiunge l’aumento del rischio di ipoglicemia riscontrato con alcuni di questi farmaci tradizionali che a sua volta incrementa il pericolo di complicanze fra cui le nefropatie, che colpiscono la maggior parte dei diabetici. Benché la compromissione della funzionalità renale sia assai diffusa in questi pazienti, spesso non viene diagnosticata in fase precoce con il rischio di non poter somministrare da subito la migliore terapia”, ha commentato il Professor Julio Rosenstock, Direttore del Centro di Endocrinologia e Diabete di Dallas al Medical City ed anche Professore in Clinica Medica alla Medical School dell’Università del Texas Southwestern, Dallas, Texas, USA. “Con Linagliptin, gli studi ci confermano che solo il cinque percento di questo farmaco viene escreto per via renale. I dati disponibili ad oggi mostrano che con Linagliptin non sarebbero necessari aggiustamenti di dosaggio, e questo potrebbe rappresentare un grande vantaggio non solo per i pazienti diabetici di tipo 2, con diagnosi di compromissione renale, ma anche per quei pazienti a rischio di sviluppare tali complicanze, rendendo più semplice per i medici la scelta della terapia ottimale per questi casi”, ha aggiunto il Professor Julio Rosenstock.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »